| Gene symbol | FURIN | Synonyms | FUR, PACE, PCSK3, SPC1 | Type of gene | protein-coding |
| Chromosome | 15 | Map location | 15q26.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | furin, paired basic amino acid cleaving enzyme | ||||
| Gene symbol | TGFB1 | Synonyms | CED, DPD1, IBDIMDE, LAP, TGF-beta1, TGFB, TGFbeta | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | transforming growth factor beta 1 | ||||
| Gene symbol | TGFB2 | Synonyms | G-TSF, LDS4, TGF-beta2 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q41 | dbXrefs | |
| Description | transforming growth factor beta 2 | ||||
| GTO ID | GTC0139 |
| Trial ID | NCT01551745 |
| Disease | Ovarian Cancer |
| Altered gene | FURIN|TGFB1|TGFB2 |
| Therapeutic/Target gene | Target gene |
| Therapy | shRNA |
| Treatment | Vigil|FANG Vaccine |
| Co-treatment | Bevacizumab |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105 |
| Year | 2012 |
| Country | United States |
| Company sponsor | Gradalis, Inc |
| Other ID(s) | CL-PTL 112 |
| Cohort 1 | |||||||||||||
|
|||||||||||||